RXST250117P25000
- 0.15
- 0.000.00%
RxSight Newsroom
Stifel Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $40
Hold Rating Issued Amidst Rising Competition and Market Uncertainty for RxSight
Stifel Downgrades RxSight to Hold, Lowers Price Target to $40
Wells Fargo Downgrades RxSight(RXST.US) to Hold Rating, Cuts Target Price to $42
RxSight Analyst Ratings
UBS Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $52
RxSight's Promising Growth With Light Adjustable Lens: A Buy Recommendation by Danielle Antalffy
Morgan Stanley Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $70
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $60
Stifel Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $65
Wells Fargo Maintains RxSight(RXST.US) With Buy Rating, Raises Target Price to $56
BofA Securities Maintains RxSight(RXST.US) With Buy Rating, Cuts Target Price to $60
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Artivion (AORT) and RxSight (RXST)
RxSight's Strong Growth and Market Positioning Earns Buy Rating From Analyst
RxSight Analyst Ratings
Jefferies Initiates RxSight(RXST.US) With Buy Rating, Announces Target Price $72
BTIG Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $59
Needham Maintains RxSight(RXST.US) With Buy Rating, Maintains Target Price $66
RxSight's Growth Trajectory: A Buy Recommendation on Strong Revenue Prospects and International Expansion